Have a feature idea you'd love to see implemented?
Let us know!
QTTB Q32 Bio Inc.
Price (delayed)
$47.66
Market cap
$574.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$15.51
Enterprise value
$494.96M
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Highlights
QTTB's EPS has soared by 73% YoY and by 50% from the previous quarter
QTTB's quick ratio has surged by 53% since the previous quarter and by 14% year-on-year
QTTB's net income is down by 21% since the previous quarter but it is up by 19% year-on-year
Q32 Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Q32 Bio's gross profit has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of QTTB
Market
Valuations
Earnings
Shares outstanding
12.06M
Market cap
$574.77M
Enterprise value
$494.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
16.98
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$65.02M
EBITDA
-$63.02M
Free cash flow
-$82.74M
Per share
Balance sheet
Liquidity
EPS
-$15.51
Free cash flow per share
-$6.92
Book value per share
$2.81
Revenue per share
$0
TBVPS
$10.38
Total assets
$124.21M
Total liabilities
$90.7M
Debt
$18.5M
Equity
$33.51M
Working capital
$94.43M
Debt to equity
0.55
Current ratio
6.49
Quick ratio
6.3
Net debt/EBITDA
1.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-56.1%
Return on equity
N/A
Return on invested capital
-121%
Return on capital employed
-60.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
QTTB stock price
How has the Q32 Bio stock price performed over time
Intraday
0.93%
1 week
-0.25%
1 month
6.81%
1 year
154.59%
YTD
335.65%
QTD
6.81%
Financial performance
How have Q32 Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$75.86M
Net income
-$65.02M
Gross margin
N/A
Net margin
N/A
Q32 Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Q32 Bio's gross profit has shrunk by 100% QoQ and by 100% YoY
QTTB's net income is down by 21% since the previous quarter but it is up by 19% year-on-year
The operating income has declined by 16% since the previous quarter but it is up by 7% year-on-year
Growth
What is Q32 Bio's growth rate over time
Valuation
What is Q32 Bio stock price valuation
P/E
N/A
P/B
16.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
QTTB's EPS has soared by 73% YoY and by 50% from the previous quarter
QTTB's equity has dropped by 72% year-on-year and by 31% since the previous quarter
Q32 Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Efficiency
How efficient is Q32 Bio business performance
Q32 Bio's return on invested capital has shrunk by 159% YoY and by 61% QoQ
The ROA has contracted by 49% YoY and by 33% from the previous quarter
Dividends
What is QTTB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for QTTB.
Financial health
How did Q32 Bio financials performed over time
The total assets is 37% greater than the total liabilities
The total liabilities has soared by 82% YoY but it has contracted by 12% from the previous quarter
The current ratio has surged by 55% since the previous quarter and by 13% year-on-year
QTTB's debt is 45% smaller than its equity
Q32 Bio's debt to equity has soared by 129% YoY and by 45% from the previous quarter
QTTB's equity has dropped by 72% year-on-year and by 31% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.